These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34656144)

  • 1. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
    Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
    Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
    Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
    J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
    Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
    PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
    Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
    Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.
    Verhamme C; de Haan RJ; Vermeulen M; Baas F; de Visser M; van Schaik IN
    BMC Med; 2009 Nov; 7():70. PubMed ID: 19909499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
    Pareyson D; Schenone A; Fabrizi GM; Santoro L; Padua L; Quattrone A; Vita G; Gemignani F; Visioli F; Solari A;
    Pharmacol Res; 2006 Dec; 54(6):436-41. PubMed ID: 17029975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2016 Jul; 11(1):92. PubMed ID: 27387831
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
    Lewis RA; McDermott MP; Herrmann DN; Hoke A; Clawson LL; Siskind C; Feely SM; Miller LJ; Barohn RJ; Smith P; Luebbe E; Wu X; Shy ME;
    JAMA Neurol; 2013 Aug; 70(8):981-7. PubMed ID: 23797954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
    Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D
    Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: an update.
    Tazir M; Hamadouche T; Nouioua S; Mathis S; Vallat JM
    J Neurol Sci; 2014 Dec; 347(1-2):14-22. PubMed ID: 25454638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited demyelinating neuropathies with micromutations of peripheral myelin protein 22 gene.
    Taioli F; Cabrini I; Cavallaro T; Acler M; Fabrizi GM
    Brain; 2011 Feb; 134(Pt 2):608-17. PubMed ID: 21252112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
    Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for fatigue in peripheral neuropathy.
    White CM; van Doorn PA; Garssen MP; Stockley RC
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD008146. PubMed ID: 25519471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.